PathAI, a provider of artificial intelligence (AI)-powered digital pathology solutions, has announced the launch of the Precision Pathology Network (PPN), a new initiative involving digital anatomic pathology laboratories.
These labs will employ PathAI’s AISight Image Management System (IMS) to pave the way for AI-powered clinical advancements in collaboration with the biopharmaceutical industry.
The Precision Pathology Network aims to provide participating laboratories with early access to AI-powered pathology innovations developed by PathAI, potentially opening new revenue avenues through the monetisation of unidentifiable real-world pathology data.
PathAI expects this development to bolster support for evidence generation studies sponsored by biopharma. Furthermore, proprietary algorithms like MET-Predict are intended to be incorporated within member workflows to enhance patient recruitment for clinical trials by identifying specific tumour types accurately.
PathAI co-founder and CEO Andy Beck said: “PathAI is the leading digital pathology company working deeply with the biopharma industry to accelerate their precision medicine goals using AI-powered pathology, who also works with a large network of pathology laboratories who are on the cutting edge and implementing digital within their workflows.
“This first-of-its-kind network will play a vital role in advancing precision diagnostics and accelerating the adoption of AI in pathology, working to ensure that these innovations translate into improved patient outcomes worldwide.”
A key component of the network is the technological foundation built on the AISight IMS platform.
Members gain prioritised access to advanced algorithmic products which are pivotal for facilitating precision biomarker testing and patient treatment solutions as these digital diagnostic tools become commercially available. These innovations will assist PPN laboratories in fast-tracking these state-of-the-art offerings, said the company.
Moreover, the Precision Pathology Network will provide a systematic framework for members to engage with translational research utilising de-identified whole slide imagery, pathology reports, and additional molecular data collaboratively with the biopharma sector. This contribution is organised and safeguarded through collaboration between PathAI and its strategic partners.
PathAI’s innovative biomarker discovery line, available via AISight, alongside tools within its PLUTO foundation model, expands access for members aiming at breakthrough biomarker exploration projects. This is expected to open further avenues for securing grants and opportunities for tailormade model co-development.
By integrating various healthcare and research institutions on this consolidated digital platform, chaired by PathAI’s technological expertise, the Precision Pathology Network fosters innovation across industry, academic and clinical domains within digital diagnostics.
The cross-institution collaboration afforded by this network aims to standardise quality control efforts while pushing forward advancements integral to precision medicine. This initiative connects pathology labs seamlessly with biopharmaceutical research and breakthroughs within an interconnected ecosystem, said the firm.
